1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-118694
    TAPI-0 Inhibitor 98.98%
    TAPI-0 是一种 TACE (TNF-α 转化酶;ADAM17) 抑制剂,IC50 为 100 nM。TAPI-0 也是一种 MMP 抑制剂,还可以减弱阻断 TNF-α。
    TAPI-0
  • HY-15507
    VGX-1027 Inhibitor 99.67%
    VGX-1027 是一种口服有效的异恶唑化合物,具有免疫调节特性。VGX-1027 靶向巨噬细胞,减少促炎性介质 TNF-α,IL-1β,IL-10 的产生。VGX-1027 通过限制细胞因子介导的免疫炎症而具有抗糖尿病作用。
    VGX-1027
  • HY-P990706
    Povetacicept Inhibitor ≥99.0%
    Povetacicept (ALPN-303) 是一种工程化 TACI 结构域的 Fc 融合蛋白,是一种双重 APRIL/BAFF 拮抗剂。Povetacicept 调节 B 淋巴细胞和致病性自身抗体,用于研究狼疮和其他 B 细胞相关的自身免疫性疾病。
    Povetacicept
  • HY-P99149
    Anti-Mouse TNFR2 Antibody (TR75-54.7) Inhibitor
    Anti-Mouse TNFR2 Antibody (TR75-54.7) 是一种抗小鼠 TNFR2 IgG 单克隆抗体。Anti-Mouse TNFR2 Antibody (TR75-54.7) 可以降低白细胞计数 (WBC),并减少一些促炎细胞因子如 CCL2 和 CXCL5 的表达。Anti-Mouse TNFR2 Antibody (TR75-54.7) 可用于研究炎症疾病和癌症如乳腺癌。
    Anti-Mouse TNFR2 Antibody (TR75-54.7)
  • HY-P99119
    Anti-Mouse 4-1BB/CD137 Antibody (3H3) Inhibitor
    Anti-Mouse 4-1BB/CD137 Antibody (3H3) 是一种抗小鼠 4-1BB/CD137 IgG2a 单克隆抗体。Anti-Mouse 4-1BB/CD137 Antibody (3H3) 通过增加 Bcl-xL 和 granzyme B 的水平有效激活记忆 T 细胞并抑制肿瘤。Anti-Mouse 4-1BB/CD137 Antibody (3H3) 可用于淋巴瘤和结肠癌等癌症的研究。
    Anti-Mouse 4-1BB/CD137 Antibody (3H3)
  • HY-P99167
    Lucatumumab

    卢卡木单抗

    Inhibitor 98.18%
    Lucatumumab (HCD122) 是一种全人抗 CD40 拮抗剂单克隆抗体,可阻断 CD40/ CD40L 介导的信号通路。Lucatumumab 可有效介导抗体依赖性细胞介导的细胞毒性 (ADCC) 和肿瘤细胞清除,可用于顽固性淋巴瘤、慢性淋巴细胞白血病 (CLL) 和多发性骨髓瘤研究。
    Lucatumumab
  • HY-P990070
    Zigakibart

    泽戈奇拜单抗

    Inhibitor 98.37%
    Zigakibart (BION-1301) 是一种 IgG4-kappa、抗 TNFSF13 (肿瘤坏死因子 (TNF) 超家族成员 13、APRIL、CD256) 人源化单克隆抗体。 Zigakibart 具有抗炎活性。
    Zigakibart
  • HY-W012732
    Isoquinoline

    异喹啉

    Inhibitor 99.58%
    Isoquinoline 是吡啶的类似物。Isoquinoline 为结构基础的生物碱,如对甲苯二异喹啉,邻苯二甲酰异喹啉和萘基异喹啉等具有抗癌活性。Berberine (属于 Isoquinoline 生物碱) 通过下调促炎/抗炎细胞因子及 Th1/Th2 细胞因子的基因表达比率在糖尿病小鼠中发挥抗炎作用。此外,一些 Isoquinoline 类化合物也具有抗抑郁、抗菌、抗疟疾和抗 HIV 活性。
    Isoquinoline
  • HY-100735
    C 87 Inhibitor 98.06%
    C 87 是一种新型小分子 TNFα 抑制剂; 高效抑制 TNFα 诱导的细胞毒性,IC50 值为 8.73 μM。
    C 87
  • HY-118250
    GSK2245035 Activator 99.79%
    GSK2245035 是一种高效的,选择性的鼻内 Toll-Like 受体 7 (TLR7) 激动剂,具有优先刺激 1 型干扰素 (IFN) 的特性。GSK2245035 对 IFNα 和TNFα 的 pEC50 分别为 9.3 和 6.5。GSK2245035 有效抑制人外周血细胞培养物中过敏原诱导的 Th2 细胞因子产生。GSK2245035 有用于哮喘的潜力。
    GSK2245035
  • HY-P99361
    Enavatuzumab

    依那妥组单抗

    Inhibitor 98.27%
    Enavatuzumab (PDL192; ABT-361) 是一种人源化 IgG1 单克隆抗体,靶向 TNF 样细胞凋亡弱诱导剂受体 (TWEAK)。TWEAK (Fn14; TNFRSF12A) 是 TWEAK 受体 (TweakR) 的天然配体,可刺激多种细胞反应。Enavatuzumab 通过直接的 TweakR 信号和抗体依赖性细胞介导的细胞毒性 (ADCC) 诱导肿瘤生长抑制。Enavatuzumab 可以主动募集和激活骨髓效应细胞来杀死肿瘤细胞。Enavatuzumab 在体外和体内抑制各种人类 TweakR 阳性癌细胞系和异种移植物的生长。
    Enavatuzumab
  • HY-P99249
    Vonlerolizumab

    珀伽利珠单抗

    Inhibitor 99.70%
    Vonlerolizumab (MOXR 0916) 是一种人源化的 IgG 激动的 OX40 特异性单克隆抗体。Vonlerolizumab 可用于癌症的研究。
    Vonlerolizumab
  • HY-P99390
    Tepoditamab Inducer ≥99%
    Tepoditamab (MCLA-117) 是一种全长人源 IgG1 双特异性单克隆抗体,可与髓系细胞的 CLEC12A 和细胞毒性 T 细胞的 CD3 结合。其中,CLEC12A 是一种髓系分化抗原。Tepoditamab 可杀伤 AML 白血病母细胞和 AML 白血病干细胞,并诱导 T 细胞介导的 AML 细胞增殖裂解。Tepoditamab 可诱导 T 细胞扩增高达 30 倍。Tepoditamab 可分别在人全血和外周血单个核细胞 (PBMC) 中引起中度至重度细胞因子 (IFNγ、IL-6、IL-8、IL-10 和 TNFα) 和 IFNγ 的释放。 Tepoditamab 可用于急性髓系白血病 (AML) 研究。
    Tepoditamab
  • HY-112275
    TNF-α-IN-1 Inhibitor 99.20%
    TNF-α-IN-1 (Compound I-7) 是一种 TNF-α 抑制剂。TNF-α-IN-1 可用于研究癌症、心脏病、自身免疫性疾病和感染。
    TNF-α-IN-1
  • HY-W040045
    Callistephin chloride Inhibitor 98.02%
    Callistephin (Pelargonidin 3-O-glucoside) chloride 是一种花青素。Callistephin chloride 通过抑制 p38 磷酸化来调节炎症 (如下调 iNOS/TNF-α/COX-2) 和凋亡 (apoptosis) 相关蛋白表达,增强 Isoflurane (HY-A0134) 对小胶质细胞损伤的保护作用。Callistephin chloride 先显著降低 ROS 水平,清除 DPPH 自由基,保护视网膜色素上皮细胞,抑制脂质过氧化。Callistephin chloride 能减轻谷氨酸兴奋性毒性,减少神经元凋亡,保护小脑颗粒神经元。Callistephin chloride 可通过诱导凋亡,抑制乳腺癌细胞的增殖和转移。
    Callistephin chloride
  • HY-15643A
    LY 303511 hydrochloride Activator 98.87%
    LY 303511 hydrochloride 是 是 LY294002 的一种结构类似物,但 LY303511 不抑制 PI3K。LY303511 可增强 SHEP-1 神经母细胞瘤细胞的TRAIL 敏感性。LY303511 可逆地阻断 MIN6 胰岛瘤细胞中的 K+ 电流 (IC50=64.6±9.1 μM)。
    LY 303511 hydrochloride
  • HY-19929
    Tanimilast Antagonist 99.49%
    Tanimilast (CHF-6001) 是一种口服有效的、选择性磷酸二酯酶 4 抑制剂 (PDE4, IC50=0.026 nM),具有强大的抗炎活性,适合局部肺给药。Tanimilast 提高细胞 cAMP 水平,并抑制 NF-κB 信号通路。Tanimilast 可用于研究阻塞性肺病。
    Tanimilast
  • HY-P990083
    Tegoprubart
    Tegoprubart 是一种针对 CD40 配体 (CD40L) 的单克隆抗体,CD40 配体是共刺激的关键介质。CD40L 的抑制会降低细胞和抗体介导的免疫,并创造一个更具耐受性的免疫环境。Tegoprubart 被证实在移植动物模型中具有体内效力。
    Tegoprubart
  • HY-P99257
    Bleselumab Inhibitor 98.97%
    Bleselumab (ASKP 1240) 是一种人抗-CD40 单克隆抗体 (mAb)。Bleselumab 以高亲和力结合人 CD40 (Kd: 0.24 nM)。Bleselumab 通过阻断 CD40 与其配体 CD40L 的相互作用来抑制免疫反应。Bleselumab 可预防器官移植排斥反应。
    Bleselumab
  • HY-115620
    AQX-016A Inhibitor 98.06%
    AQX-016A 是一种口服有效的 SHIP1 激动剂。AQX-016A 可以在体外激活重组 SHIP1 酶并刺激 SHIP1 活性。AQX-016A 还可抑制 PI3K 通路和 TNFa 的产生,可用于各种炎症疾病的研究。
    AQX-016A
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.